Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.

Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR.

CMAJ. 2001 Oct 16;165(8):1011-9.

2.

Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.

Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR.

CMAJ. 2002 Jun 25;166(13):1655-62.

3.

The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.

Grootendorst PV, Marshall JK, Holbrook AM, Dolovich LR, O'Brien BJ, Levy AR.

Health Serv Res. 2005 Oct;40(5 Pt 1):1297-317.

4.

Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM.

CMAJ. 2002 Mar 19;166(6):737-45.

5.

Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.

Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ.

Clin Pharmacol Ther. 2003 Oct;74(4):388-400.

PMID:
14534526
6.

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, Sturm H.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005979. Review. Update in: Cochrane Database Syst Rev. 2014;10:CD005979.

PMID:
16625648
7.

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, Kösters JP, Vacca C, Machado M, Diaz Ayala DH, Oxman AD.

Cochrane Database Syst Rev. 2014 Oct 16;10:CD005979. doi: 10.1002/14651858.CD005979.pub2. Review.

PMID:
25318966
8.

Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.

Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M.

Med Care. 2004 Jul;42(7):653-60.

PMID:
15213490
9.

Evaluating reference-based pricing: initial findings and prospects.

Narine L, Senathirajah M, Smith T.

CMAJ. 1999 Aug 10;161(3):286-8.

10.

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB.

N Engl J Med. 2002 Mar 14;346(11):822-9.

11.

Coverage of drug costs: reference-based pricing.

McGregor M.

Can J Cardiol. 1998 May;14(5):666-8.

PMID:
9627520
12.

Reference-based pricing in British Columbia: implications for cardiologists--an analysis.

Boulet AP, Tessier G.

Can J Cardiol. 1997 Jan;13(1):46-51. Review.

PMID:
9039064
13.

Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.

Ioannides-Demos LL, Ibrahim JE, McNeil JJ.

Pharmacoeconomics. 2002;20(9):577-91. Review.

PMID:
12141886
15.

Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.

Augurzky B, Göhlmann S, Gress S, Wasem J.

Health Econ. 2009 Apr;18(4):421-36. doi: 10.1002/hec.1376.

PMID:
18677725
16.

Reference-based pricing (RBP) of prescription drugs.

Holbrook A, O'Brien B, Grootendorst P.

Can J Cardiol. 1997 Jul;13(7):689-90. No abstract available.

PMID:
9251582
17.
18.
19.
20.

European healthcare policies for controlling drug expenditure.

Ess SM, Schneeweiss S, Szucs TD.

Pharmacoeconomics. 2003;21(2):89-103.

PMID:
12515571
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk